|
About the Statistics and Pharmacometrics (SxP) category
|
|
0
|
1336
|
February 19, 2016
|
|
Summary Statistics for Blinded Clinical Trial Results
|
|
4
|
452
|
September 27, 2019
|
|
Statistics and Pharmacometrics Blog
|
|
7
|
1405
|
October 12, 2017
|
|
DIA ADSWG Adaptive Dose Individualization (announcement & invitation)
|
|
0
|
959
|
August 25, 2017
|
|
Symposium on Dose Selection for Cancer Treatment Drugs
|
|
0
|
940
|
April 24, 2017
|
|
What are the sticking points between statistics and pharmacometrics?
|
|
9
|
2361
|
April 19, 2017
|
|
Variability, Uncertainty, and Error
|
|
4
|
3875
|
March 29, 2017
|
|
When is a result worth noting? A quick thought on pharmacometrics and multiplicity
|
|
5
|
1740
|
March 15, 2017
|
|
Optimal PK sampling shedule
|
|
5
|
3038
|
March 13, 2017
|
|
Survey to Help in Planning
|
|
0
|
957
|
March 10, 2017
|
|
2016 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop
|
|
0
|
1067
|
October 19, 2016
|
|
Announcing SxP (Statistics and Pharmacometrics Interest Group)
|
|
0
|
1212
|
May 27, 2016
|
|
My Career as a Pharmacometrician and Commentary on the Overlap Between Statistics and Pharmacometrics in Drug Development
|
|
0
|
1574
|
February 20, 2016
|
|
ACoP